Cargando…

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

Subcutaneous (SC) administration of the proteasome inhibitor bortezomib was approved in the United States and European Union in 2012. There is limited guidance regarding how to administer SC bortezomib and a general lack of clear direction on optimal techniques for administering SC chemotherapy inje...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Jasmine R., Beegle, Nancy L., Zhu, Yanyan, Hanisch, Ellen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677804/ https://www.ncbi.nlm.nih.gov/pubmed/26705492

Ejemplares similares

Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
por: Kurtin, Sandra, et al.
Publicado: (2012)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Subcutaneous vaccine administration – an outmoded practice
por: Cook, Ian F.
Publicado: (2020)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
por: McCloskey, Conor, et al.
Publicado: (2022)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study
por: Rommers, Mirjam K, et al.
Publicado: (2006)

Bortezomib in Kidney Transplantation
por: Raghavan, Rajeev, et al.
Publicado: (2010)

The Oncology Nurse Prescribing: A Catalonian Survey
por: Fernández-Ortega, Paz, et al.
Publicado: (2016)

The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection
por: Jin, Jing-fen, et al.
Publicado: (2015)

An Overview of Bortezomib-Induced Neurotoxicity
por: Meregalli, Cristina
Publicado: (2015)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
por: Ye, Ziqi, et al.
Publicado: (2019)

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
por: Bittner, Beate, et al.
Publicado: (2018)

Patients' independence of a nurse for the administration of subcutaneous anti-TNF therapy: A phenomenographic study
por: Larsson, Ingrid, et al.
Publicado: (2010)

A survey of subcutaneous blood flow in patients with SMID and subcutaneous ceftazidime administration using mentholated warm compresses in healthy subjects
por: Ebihara, Tsuyoshi, et al.
Publicado: (2016)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Why bortezomib cannot go with ‘green’?
por: Jia, Li, et al.
Publicado: (2013)

Bortezomib in autoimmune hemolytic anemia and beyond
por: Pasquale, Raffaella, et al.
Publicado: (2021)

Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study
por: Risselada, Marije, et al.
Publicado: (2017)

A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
por: Lee, Keun-Wook, et al.
Publicado: (2005)

Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration
por: Miller, Meagan E., et al.
Publicado: (2023)

Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
por: Yamamoto, Shota, et al.
Publicado: (2021)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Pilot study on the effect of subcutaneous administration of lactated Ringer's solution on biochemistry parameters in healthy euvolemic cats.
por: Smith, M. Ryan, et al.
Publicado: (2016)

Subcutaneous Fluid Administration: A Potentially Useful Tool in Prehospital Care
por: Arthur, Annette O., et al.
Publicado: (2012)

A survey of nurses' experience integrating oncology clinical and academic worlds
por: Haase, Kristen R., et al.
Publicado: (2021)

Oncology nursing on the move: a contemporary issue on Chinese oncology nursing in cancer care
por: Li, Yingyang, et al.
Publicado: (2023)

Pyridoxine induced neuropathy by subcutaneous administration in dogs
por: Chung, Jin-Young, et al.
Publicado: (2008)

Minimization of administration route errors with subcutaneous rituximab
por: Liptrott, Sarah, et al.
Publicado: (2016)

Treatment of Phthisis by Subcutaneous Administration of Carbolic Acid
Publicado: (1886)

Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration
por: Bianchi, Gerolamo, et al.
Publicado: (2016)

Potential Benefits of the Self-Administration of Subcutaneous Methotrexate with Autoinjector Devices for Patients: A Review
por: Tornero Molina, Jesús, et al.
Publicado: (2021)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g7j3nnnb9pbl04jpe485t0prmc